Cancer research is a crucial pillar for countries to deliver more affordable, higher
quality, and more equitable cancer care. Patients treated in research-active hospitals
have better outcomes than patients who are not treated in these settings. However,
cancer in Europe is at a crossroads. Cancer was already a leading cause of premature
death before the COVID-19 pandemic, and the disastrous effects of the pandemic on
early diagnosis and treatment will probably set back cancer outcomes in Europe by
almost a decade.
Sistine Chapel or Chapel Hill? Art + Transit program searches for bus ceiling artists dailytarheel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailytarheel.com Daily Mail and Mail on Sunday newspapers.
Tagrisso demonstrated 5 5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years
Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease